Stakeholders
Topics
Institute for Value-Based Medicine
About AJMC
CME/CE
Subscribe
- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Myelodysplastic Syndromes
Latest News
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024
Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
